Recursion Pharmaceuticals, Inc. - Class A Common Stock — Cash Flow (NASDAQ:RXRX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -158.61 M-83.52 M-287.78 M-359.17 M-371.81 M -350.48 M Cash from investing activities -271.74 M193.25 M-10.23 M260.06 M-16.87 M -6.09 M Cash from financing activities 458.54 M154.34 M140.13 M304.12 M521.53 M 378.61 M Free cash flow -158.61 M-83.52 M-287.78 M-359.17 M-380.44 M -354.26 M

News

Tempus AI Just Had Their Entire Strategy Validated By Moderna’s Vaccine Advance (TEM)

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RXRX) 2026-08-09

RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know

Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today